Natus Medical Price on September 11, 2017 Breakdown

BABY -- USA Stock  

USD 34.25  0.20  0.58%

Macroaxis considers Natus Medical to be not too volatile. Natus Medical Incorp has Sharpe Ratio of -0.0572 which conveys that Natus Medical Incorp had -0.0572% of return per unit of risk over the last 1 month. Macroaxis philosophy towards estimating risk of any stock is to look at both systematic and un-systematic factors of the business, including all available market data and technical indicators. Natus Medical exposes twenty-one different technical indicators which can help you to evaluate volatility that cannot be diversified away. Please be advised to verify Natus Medical Incorporated Mean Deviation of 1.82 and Risk Adjusted Performance of 0.017534 to check out risk estimate we provide.

Natus Medical Valuation Near September 11, 2017

 Open High Low Close Volume
  33.05    33.20    32.70    32.90    310,629  
  33.10    35.90    33.10    35.70    598,431  
  35.45    36.70    35.00    36.35    507,954  
Backtest Natus Medical  |  Natus Medical History  |  Natus Medical Valuation   PreviousNext  
September 11, 2017
Open Value
Closing Value
Target Odds

Natus Medical Trading Date Momentum on September 11, 2017

On September 12 2017 Natus Medical Incorporated was traded for 36.35  at the closing time. The top price for the day was 36.70  and the lowest listed price was  35.00 . The trading volume for the day was 508 K. The trading history from September 12, 2017 was a factor to the next trading day price appreciation. The overall trading delta against the next closing price was 1.82% . The trading delta at closing time against the current closing price is 3.64% .

Natus Medical Incorp Fundamentals Correlations and Trends

Price Boundaries

Natus Medical Period Price Range

September 11, 2017
2.60  7.85%
Check also Trending Equities. Please also try Positions Ratings module to determine portfolio positions ratings based on digital equity recommendations. macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance.